Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08KCJ
|
|||
| Former ID |
DIB015801
|
|||
| Drug Name |
ABY-025
|
|||
| Indication | Bladder cancer [ICD-11: 2C94; ICD-9: 188] | Phase 1/2 | [1] | |
| Company |
Affibody Holding AB
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01858116) PET Study of Breast Cancer Patients Using [68Ga]ABY-025. U.S. National Institutes of Health. | |||
| REF 2 | Targeting of HER2-expressing tumors using 111In-ABY-025, a second-generation affibody molecule with a fundamentally reengineered scaffold. J Nucl Med. 2010 Jul;51(7):1131-8. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.